Ferronova筹集了6M元用于推进纳米粒子技术, 改善手术中的癌症检测, 临床试验正在进行中, Ferronova raised $6M to advance nanoparticle tech that improves cancer detection in surgery, with a clinical trial underway and U.S. expansion planned.

澳大利亚Ferronova医疗技术公司筹集了600万美元,用于推进其纳米粒子成像制导外科技术,其目的是在手术期间改进癌症的检测,特别是胃癌和食道癌的检测。 Australian medtech company Ferronova has raised $6 million to advance its nanoparticle-based image-guided surgery technology, designed to improve cancer detection during operations, particularly for stomach and oesophageal cancers. 该系统利用超级对地磁氧化铁纳米粒子来突出淋巴结中的癌症细胞,目的是减少未检测到的残余疾病。 The system uses super-paramagnetic iron oxide nanoparticles to highlight cancerous cells in lymph nodes, aiming to reduce undetected residual disease. 这笔资金由包括Uniseed/Unisuper和革新制药公司在内的现有投资者牵头,使A系列资金总额达到1 750万美元。 The funding, led by existing investors including Uniseed/UniSuper and Renew Pharmaceuticals, brings total Series A financing to $17.5 million. 澳大利亚各大研究中心正在进行60个病人临床试验,有54名病人注册,预计2026年初将获得结果。 A 60-patient clinical trial is underway across major Australian research centers, with 54 patients enrolled and results expected in early 2026. 该公司计划扩展到美国,目的是提高全球每年确诊180万癌症患者的外科精确度。 The company plans to expand into the U.S. and aims to improve surgical precision for the 1.8 million people diagnosed globally with these cancers annually.